Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs AZO GANTANOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Urinary tract infections (UTIs) when sulfonamide therapy is indicated (FDA),Pain relief of urinary tract irritation (phenazopyridine component)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (Cr Cl >80 m L/min); prolonged to 20-50 hours in CKD (Cr Cl <30 m L/min); phenazopyridine half-life: 9-11 hours
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Sulfamethoxazole is primarily metabolized by N-acetylation in the liver (N-acetyltransferase 2); phenazopyridine is metabolized in the liver via glucuronidation and sulfation.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Sulfamethoxazole: 65-70% bound to albumin; phenazopyridine: >99% bound (mainly to albumin)
4-6 L/kg; large Vd indicates extensive tissue distribution
Sulfamethoxazole: 0.21-0.28 L/kg (for a 70 kg person: ~15-20 L); phenazopyridine: 4.5-5.5 L/kg (extensive tissue binding, e.g., urinary tract)
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral sulfamethoxazole: 85-95% (well absorbed); phenazopyridine: approximately 90% absorbed
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Sulfamethoxazole/Trimethoprim: Cr Cl >30 m L/min: no adjustment; Cr Cl 15-30 m L/min: reduce standard dose by 50% or extend interval to 24 hours; Cr Cl <15 m L/min: contraindicated. Phenazopyridine: contraindicated in renal impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Sulfamethoxazole/Trimethoprim: Child-Pugh A: no adjustment; Child-Pugh B: use with caution, no specific dose reduction; Child-Pugh C: contraindicated (risk of hepatotoxicity). Phenazopyridine: cautious use in severe hepatic impairment.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Sulfamethoxazole/Trimethoprim: 6-12 mg/kg/day of trimethoprim component divided every 12 hours; maximum 320 mg trimethoprim/day. Phenazopyridine: not recommended in children <12 years.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Sulfamethoxazole/Trimethoprim: monitor renal function; reduce dose if Cr Cl <30 m L/min. Increased risk of hyperkalemia and sulfonamide-induced adverse effects. Phenazopyridine: cautious use due to potential renal impairment and CNS effects.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Sulfonamides, including sulfamethoxazole, may cause severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Risk of hypersensitivity reactions including SJS/TEN; blood dyscrasias (agranulocytosis, aplastic anemia); hepatotoxicity; renal impairment; photosensitivity; interference with urine glucose tests.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to sulfonamides or phenazopyridine; porphyria; severe renal impairment (Cr Cl <30 m L/min); G6PD deficiency; infants <2 months; pregnancy at term; lactation.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Avoid foods high in vitamin K (e.g., leafy greens) as sulfamethoxazole may potentiate warfarin effects. Maintain adequate fluid intake; dehydration increases crystalluria risk. No specific food avoidance required beyond general hydration.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; second and third trimesters – Risk of kernicterus in neonate due to bilirubin displacement; avoid near term. Trimethoprim: First trimester – Folate antagonist, increased risk of neural tube defects and cardiovascular anomalies; second and third trimesters – No specific documented risks but theoretical folate antagonism.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Phenazopyridine: Excreted in breast milk; significance unknown; use caution. Sulfamethoxazole: Excreted in breast milk; M/P ratio ~0.2-0.3; risk of kernicterus in jaundiced or G6PD-deficient infants; avoid in nursing mothers of ill or premature infants. Trimethoprim: Excreted in breast milk; M/P ratio ~0.8-1.0; considered compatible by AAP but monitor infant for folate deficiency.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Pregnancy alters pharmacokinetics: Increased renal clearance may reduce sulfamethoxazole and trimethoprim levels; however, no dose adjustment is routinely recommended due to lack of data. Standard doses for urinary tract infection: one tablet (phenazopyridine 200 mg/sulfamethoxazole 400 mg/trimethoprim 80 mg) four times daily. Use lowest effective dose for shortest duration.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
AZO GANTANOL combines phenazopyridine (a urinary analgesic) with sulfamethoxazole (a sulfonamide antibiotic). Monitor for sulfonamide hypersensitivity reactions (e.g., Stevens-Johnson syndrome). Phenazopyridine discolors urine orange-red; advise patients to avoid confusion with hematuria. Adjust sulfamethoxazole dose in renal impairment (Cr Cl <30 m L/min contraindicated).
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take with a full glass of water to reduce risk of crystalluria.,Urine may turn orange-red; this is harmless and subsides after stopping the drug.,Complete full course even if symptoms improve; do not skip doses.,Avoid prolonged sun exposure; sulfonamides cause photosensitivity.,Report rash, fever, sore throat, or unusual bruising immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs AZO GANTANOL, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. AZO GANTANOL is a Sulfonamide Antibiotic that works by Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and AZO GANTANOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of AZO GANTANOL is: AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and AZO GANTANOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. AZO GANTANOL is classified as Category C. Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.